Home MarketDr. Lal Pathlabs Ltd.

Dr. Lal Pathlabs Ltd. Stock Info: As on 2017-09-20 15:56:44

Nse

802.15

0.60(0.07%)
Change%
52 Week Range
762.15
3.00
1,280.00
21.00
Open807.90
Day's Range641.24 - 961.86
Value Traded (in ₹ Cr.) 1.71

Bse

803.95

2.65(0.33%)
Change %
52 Week Range
762.70
3.00
1,278.55
21.00
Open800.00
Day's Range641.04 - 961.56
Value Traded (in ₹ Cr.) 0.26

Stock Exchange

Category No. Of Shares Share %
ForeignPromoters 0.00 0.00%
IndianPromoters 48,265,226.00 57.92%
Mutual Funds/UTI 5,168,647.00 6.20%
FII 8,820,587.00 10.58%
Employee 0.00 0.00%
Public 3,470,275.00 4.16%
Government 0.00 0.00%
Others 15,293,892.00 18.35%
More

Key Statistics

Valuation Measures
Market Cap / Sales Ratio 9.95
Basic EPS (Rs.) 15.31
Cash EPS 19.08
BVPerShare Excl 57.88
Operating Revenue 92.58
PBDITPerShare 27.12
Dividend 2.45
NPPerShare 15.21
Current Ratio 4.68
Quick Ratio 4.52
PriceToBV 15.92
Earnings 0.01
PBDIT Margin 29.29
PBT Margin 25.05
NP Margin 16.42
Return On Assets 21.25
Retention Ratios 83.87
Parameter Mar-16 (₹ Cr.) Yoy%change
Total Income 785.81
Total Expenses 594.05
EBITDA 224.25
PBT 191.75
PAT 125.75
Net Income 125.75
More
Parameter Mar-16 (₹ Cr.) 6M % change
Total Income 384.69
Total Expenses 268.78
EBITDA 99.39
PBT 132.23
PAT 92.43
Net Income 0.00
More
Total Assets
Total Assets
Parameter Mar-16 (₹ Cr.) Yoy%change
Total share capital 82.68
Net worth 478.51
Investments 74.18
Total Liability 591.72
Total debt 0.00
Net block 133.88
Total Assets 591.72
Parameter Mar-16 (₹ Cr.) 6M % change
Total share capital 81.26
Net worth 319.24
Investments 49.36
Total Liability 449.18
Total debt 0.00
Net block 119.97
Total Assets 449.18
Company Curr Price Prev. Close Change% W's Low/High

Apollo Hospitals Enterprise Ltd.

1066.4 1057.35 0.86
10481076

Fortis Healthcare Ltd.

153.55 153.55 0
148.4158.4

Healthcare Global Enterprises Ltd.

267.45 263.95 1.33
255272

Indraprastha Medical Corporation Ltd.

52.7 52.7 0
52.554.15

Kovai Medical Center and Hospital Ltd.

641.65 624.85 2.68
629.9649.9

Lotus Eye Hospital and Institute Ltd.

29.95 30.95 -3.23
28.5534.9

Marico Kaya Enterprises Ltd.

1547.05 1582.55 -2.24
1535.051589
Company Curr Price Prev. Close Change% W's Low/High

ADS Diagnostic Ltd.

11.34 10.8 0
11.3411.34

Apollo Hospitals Enterprise Ltd.

1064 1057.5 0.61
10501074.9

Birla Pacific Medspa Ltd.

0.28 0.27 0
0.270.28

CDR Health Care Ltd.

7.58 2.6 0
7.227.58

Chennai Meenakshi Multispeciality Hospital Ltd.

12.1 12.7 -4.72
12.112.7

Dhanvantri Jeevan Rekha Ltd.

33.25 35 -5
3337

Dolphin Medical Services Ltd.

1.23 1.21 1.65
1.111.25
More
Parameter Mar-16(in ₹ Cr.)
Cash from operating activities 142.25
Cash from investing activities -148.14
Cash from financing activities 0.99
Net change in cash -4.89

Stock Held By Mutual Fund Schemes

Scheme Holding (%)
SBI Magnum Balanced Fund 0.90%
Franklin India Prima Plus 1.04%
SBI Blue Chip Fund 0.46%
Franklin India Prima Fund 1.12%
SBI Magnum Midcap Fund 1.68%
SBI Magnum Global Fund 1.82%

NBCC to launch 1,000 flats for sale during festival

State-owned construction firm NBCC will launch about 1,000 flats for sale in this festival season and is in discussion with the government to develop affordable housing projects on surplus land with PSUs. The company is also in talks with the government for developing islands in Andaman and Nicobar and Lakshadweep, its Chairman and Managing Director Anoop Kumar Mittal said. We have been appointed as land management agency for the surplus land with sick PSUs. We are in close discussion with the government to develop affordable housing projects on some of the land parcels, he told reporters. On developing island, Mittal said the company has experience in developing islands in Maldives and expects to bag similar projects in India. We will be launching 1,000 flats as well as commercial area across the country including Delhi-NCR in this festival. The flats will be in the price range of Rs 15 lakh to Rs 1 crore, he said. Asked about taking over stressed projects of Jaypee Infratech and Amrapali, he said the company has not received any offer from any stakeholder including buyers, builders or the government. However, he said the company would certainly consider if there is any opportunity, provided projects should be viable and not bring bad name to the NBCC. On land purchase from Air India, Mittal said the company had signed an MoU with Air India for monetisation of surplus land assets of the national carrier, but there has not been much progress. However, the CMD said that the company has recently bought a land parcel from Air India in Mauritius for Rs 3 crore. Two years back, it had bought another land parcel from Air India in Coimbatore for Rs 25 crore. Mittal said two land parcels in Vasant Vihar and Baba Kharag Singh Marg in Delhi were given on lease to Air India by the government and the same is being returned to the Ministry of Housing and Urban Affairs. The company could develop projects on these two land parcels, he added. Mittal said the company has an order book of Rs 75,000 crore and the same is likely to touch Rs 1 lakh crore in the next few months. The company has an order book of Rs 700 crore from overseas. On developing railway stations, he said the company has bagged 10 projects and would like to develop at least 4-5 projects before acquiring more such projects from the Railway Ministry. Among major projects, NBCC has bagged over Rs 2,000 crore project to develop integrated exhibition-cum-convention centre for ITPO at Pragati Maidan. NBCC, which is under the administrative control of Ministry of Housing and Urban Affairs, is present in three main segments - Project Management Consultancy (PMC), Real Estate Development and EPC Contracting.

20-09-2017 17:10

NTPC wins Bhubaneswar round of Tata Crucible Corporate Quiz

National Thermal Power Corporation Ltd has emerged the winner of the Bhubaneswar regional round of Tata Crucible Corporate Quiz, 2017. Around 50 teams from prominent corporate houses across the state capital participated in the quiz, which will traverse 25 cities in India, a Tata Group release said. Chandan Shahi and Sujit Varkey of NTPC will compete with winning teams from five cities in the zonal finals. Soubhagya Jena and Gursheel Singh Sahni from Reckitt Benckiser were declared as the runners-up. Suresh G Menon, vice-president and general manager - Tata Consultancy Services Ltd (Eastern Region), yesterday felicitated the winners, who were awarded Rs 75,000, while the runners-up took home a prize money of Rs 35,000. The Tata Crucible Corporate Quiz, 2017 format is based on the concept of 'Real-Time Strategy', involving different rounds, with decision-making and strategy being the key to win the title, the release said. The national winners will get a prize money of Rs 5 lakh, along with the Tata Crucible Trophy, it added.

20-09-2017 15:31

Unichem Lab gets USFDA nod for Ibesartan, Hydrochlorothiazide Tablets

Drug major Unichem Laboratories on Wednesday said it has received ANDA approval from the USFDA for Ibesartan and Hydrochlorothiazide Tablets USP, 150mg/12.5mg and 300 mg/12.5 mg which are therapeutically equivalent to Avalide tablets 150 mg/12.5 mg and 300mg/12.5 mg of Sanofi – Aventis US LLC. “Ibesartan and Hydrochlorothiazide is a combination of Ibesartan, an angiotensin II receptor antagonist and Hydrochlorothiazide, a thiazide diuretic. The product is indicated for hypertension in patients likely to need multiple drugs to achieve their blood pressure goals,” said Unichem Laboratories in a filing to the Bombay Stock Exchange. The product will be commercialised from Unichem’s Ghaziabad plant. API will also be made at Pithampura/Roha API plants, it added. Meanwhile, shares of company were trading at Rs 245 apiece, down 1.33 per cent, from previous close on the BSE at 15:20 hours.

20-09-2017 15:12

GIPCL bags 75 MW solar power projects from GUVNL

Gujarat Industries Power Company (GIPCL) said that it has emerged as one of the successful Bidders for the 75 MW Solar Power Project in the e-reverse auction conducted by Gujarat Urja Vikas Nigam (GUVNL). “GIPCL has emerged as one of the successful Bidders for the 75 MW Solar Power Project in the e-reverse auction conducted by Gujarat Urja Vikas Nigam (GUVNL) on September 19, 2017 for 500 MW Solar Power Projects, in the State of Gujarat. on September 19, 2017 for 500 MW Solar Power Projects, in the State of Gujarat,” the company said in a filing to the Bombay Stock Exchange. GIPCL is engaged in business of Electrical Power Generation. The company has a vision to transform itself into a national level power sector enterprise. Meanwhile, shares of the company were trading at Rs 142.65 apiece, up 2.55 per cent from the previous close at 14:25 hours on BSE.

20-09-2017 14:22

PGCIL board approves Rs 198.50 cr for Baharampur unit

State-run electric utilities company Power Grid Corporation of India on Wednesday said its board has approved investment worth Rs 198.49 crore for Baharampur (POWERGRID) –Bheramara, Bangladesh. “The POWERGRID boards of directors in their meeting on September 19, 2017, have accorded investment approval for Baharampur (POWERGRID) –Bheramara, Bangladesh 2nd 400kV D/c Transmission Line (Indian Portion) at an estimated cost of Rs 198.49 crore,” Power Grid Corporation of India said in a filing to the Bombay Stock Exchange. The company further said that the commissioning schedule for plant is 24 months from the date of investment approval. Meanwhile, shares of company were trading at Rs 213.6 apiece, down 0.81 per cent, from previous close on the BSE at 14:10 hours.

20-09-2017 13:59

Dr. Lal Pathlabs Ltd - Investor Presentation

Pursuant to Reg. 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Regulations'), please find attached herewith Corporate Presentation of the Company.

The aforesaid presentation is also available on the Company's website - www.lalpathlabs.com

We request you to please take the same on record.

19-Sep-2017 11:38 AM

Dr. Lal Pathlabs Ltd - Investor Presentation

Dr. Lal Path Labs Ltd. has informed the Exchange regarding Investor Presentation

19-Sep-2017 11:30 AM

Dr. Lal Pathlabs Ltd - Analysts/Institutional Investor Meet/Con. Call Updates

Dr. Lal Path Labs Ltd. has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates

18-Sep-2017 10:52 AM

Dr. Lal Pathlabs Ltd - Analyst / Investor Meet - Intimation

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Regulations'), the details of proposed schedule of Analyst/Institutional Investor meetings are as per attachment.

18-Sep-2017 10:52 AM

Dr. Lal Pathlabs Ltd - Analyst / Investor Meet - Intimation

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Regulations'), the details of proposed schedule of Analyst/Institutional Investor meetings are as per attachment

15-Sep-2017 12:16 PM

Dr. Lal Pathlabs Ltd - Investor Presentation

Pursuant to Reg. 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Regulations'), please find attached herewith Corporate Presentation of the Company.

The aforesaid presentation is also available on the Company's website - www.lalpathlabs.com

We request you to please take the same on record.

19-Sep-2017 11:38 AM

Dr. Lal Pathlabs Ltd - Analyst / Investor Meet - Intimation

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Regulations'), the details of proposed schedule of Analyst/Institutional Investor meetings are as per attachment.

18-Sep-2017 10:52 AM

Dr. Lal Pathlabs Ltd - Analyst / Investor Meet - Intimation

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Regulations'), the details of proposed schedule of Analyst/Institutional Investor meetings are as per attachment

15-Sep-2017 12:16 PM

Corporate Details

About Management

Late Dr. Major S.K. Lal, commenced the business of providing pathology services and maintaining a blood bank in the year 1949 through sole proprietorship M/s Central Clinical Laboratory and M/s Blood Bank Transfusion Centre. The business of diagnostic and related healthcare tests and services now continues to be provided by the Company. Subsequently, Late Dr. Major S.K. Lal and (Hony.) Brig. Dr. Arvind Lal entered into a partnership under the name 'Central Clinical Laboratory', pursuant to a partnership deed dated March 21, 1975, with the partnership deemed to have commenced from December 1, 1974. The partnership firm was formed to provide pathology services under the name `Central Clinical Laboratory' and to maintain a blood bank for the supply of blood to patients and hospitals under the name `Blood Transfusion Centre', both to be undertaken at the Registered Office of the Company. On December 5, 1977, following the demise of Late Dr. Major S.K. Lal, Late Ms. Vimla Lal, wife of Late Dr. Major S.K. Lal, was inducted into the partnership with (Hony.) Brig. Dr. Arvind Lal. Following Late Ms. Vimla Lal's demise, Dr. Vandana Lal was inducted into the partnership by a deed of partnership dated January 2, 2007. Accordingly, as on date, Central Clinical Laboratory is a 50:50 partnership between Dr. Vandana Lal and (Hony.) Brig. Dr. Arvind Lal. the Company was incorporated as `Dr. Lal PathLabs Private Limited', a private limited company under the Companies Act, 1956, with a certificate of incorporation granted by the RoC on February 14, 1995 at Delhi. The business of the partnership firm Central Clinical Laboratory is now undertaken by the Company, while Central Clinical Laboratory does not undertake any business operations. the Company was converted into a public company pursuant to a special resolution of the shareholders of the Company at an EGM held on August 7, 2015. Consequently, the name of the Company was changed to `Dr. Lal PathLabs Limited' and a fresh certificate of incorporation pursuant to the change of name was granted by the RoC on August 19, 2015. Awards and accreditations : 2001 -Received the ISO 9001:2008 certification for the quality management system for performance of routine and advanced diagnostic pathology testing services, including in clinical trials. 2002 -Fully accredited by the College of American Pathologists' Laboratory Accreditation Program. 2008 -Awarded the CNBC TV18 Emerging India Award 2008 by ICICI Bank Business Banking in the pharmaceuticals and chemicals category. 2010 -Franchisor of the Year in healthcare, at the Franchise Plus Awards. -Honourable mention in the healthcare category at the Milagrow Trailblazers Brand Innovator Awards. 2012 -Diagnostic Service Provider Company of the Year, by Frost & Sullivan at the 4th Annual India Healthcare Excellence Awards. -Named a Computerworld Honours Laureate by the Computerworld Honours Program for innovative use of information technology to conduct research, develop new diagnostic methods and services and improve quality and access of patients to healthcare. 2013 -Best Diagnostic Company in India at the VC Circle Healthcare Summit. 2014 -Received the ISO 27001:2013 certification for the information management system for providing data center services and supporting functions. -Received an NABL certificate of accreditation under standard ISO 15189:2012 for "Medical Laboratories - Requirements for Quality and Competence" for medical testing, for National Reference Laboratory. 2015 -Data Quest Technology Award for Excellence in the implementation and use of technology for business benefits in the 'Cloud' category. -Received the certificate of affiliation from the Healthcare Sector Skill Council for role as medical laboratory technician in relation to institute at Gurgaon, Haryana, India. Major events and milestones : 2005 & 2007 -Investment by WestBridge I Investments Holdings. 2008 -Acquisition of Paliwal Medicare Private Limited and Paliwal Diagnostics Private Limited. 2010 -Establishment of the National Reference Laboratory. 2010 & 2013 -Investment pursuant to purchase of shares by Wagner Limited from WestBridge I Investment Holdings. 2013 -Investment pursuant to purchase of shares by WestBridge Crossover Fund, LLC from WestBridge I Investment Holdings. -Investment by SIH. 2014 -Acquisition of APL Clinical Institute of Clinical Laboratory & Research Private Limited. 2015 -Amalgamation of Sanya Chemicals Private Limited, Amolak Diagnostics Private Limited, Medex Healthcare Private Limited, Medicave Diagnostic Centre Private Limited, Medicave Medical Systems Private Limited and the Company.

Registered Office

12th Floor, Tower B, SAS Tower, Sector 38, Medicity,

0124-3016500,,,      0124-4234468,

cs@lalpathlabs.com

https://www.lalpathlabs.com

Registrar Details

Link Intime India Pvt. Ltd.